PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $517.00K; Additional Paid in CapitalUSD $1.62B; Retained Earnings (Accumulated Deficit)USD $-1.33B; Stockholders' Equity Attributable to ParentUSD $286.89M.
- 2026-03-31: Common Stock, Value, IssuedUSD $530.00K; Additional Paid in CapitalUSD $1.63B; Retained Earnings (Accumulated Deficit)USD $-1.31B; Stockholders' Equity Attributable to ParentUSD $312.62M.
- 2025-12-31: Common Stock, Value, IssuedUSD $538.00K; Additional Paid in CapitalUSD $1.63B; Retained Earnings (Accumulated Deficit)USD $-1.35B; Stockholders' Equity Attributable to ParentUSD $280.47M.
- 2025-09-30: Common Stock, Value, IssuedUSD $538.00K; Additional Paid in CapitalUSD $1.62B; Retained Earnings (Accumulated Deficit)USD $-1.32B; Stockholders' Equity Attributable to ParentUSD $294.99M.
PROTHENA CORPORATION PUBLIC LIMITED COMPANY Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $517.00K | $1.62B | $-1.33B | $286.89M | $286.89M | (m) | 3 month · $7.88M | (m) | (m) |
| 2026-03-31 | $530.00K | $1.63B | $-1.31B | $312.62M | $312.62M | (m) | 3 month · $6.92M | (m) | (m) |
| 2025-12-31 | $538.00K | $1.63B | $-1.35B | $280.47M | $280.47M | (m) | 12 month · $37.64M | (m) | (m) |
| 2025-09-30 | $538.00K | $1.62B | $-1.32B | $294.99M | $294.99M | (m) | 3 month · $7.20M | (m) | (m) |
| 2025-06-30 | $538.00K | $1.61B | $-1.29B | $324.33M | $324.33M | (m) | 3 month · $12.42M | (m) | (m) |
| 2025-03-31 | $538.00K | $1.60B | $-1.16B | $437.68M | $437.68M | (m) | 3 month · $10.95M | (m) | (m) |
| 2024-12-31 | $538.00K | $1.59B | $-1.10B | $486.93M | $486.93M | (m) | 12 month · $45.96M | (m) | (m) |
| 2024-09-30 | $538.00K | $1.58B | $-1.04B | $534.36M | $534.36M | (m) | 3 month · $11.02M | (m) | (m) |
| 2024-06-30 | $538.00K | $1.57B | $-985.38M | $581.92M | $581.92M | (m) | 3 month · $12.04M | (m) | (m) |
| 2024-03-31 | $537.00K | $1.55B | $-1.05B | $502.40M | $502.40M | (m) | 3 month · $12.38M | (m) | (m) |
| 2023-12-31 | $537.00K | $1.54B | $-980.03M | $561.37M | $561.37M | (m) | 12 month · $40.91M | (m) | (m) |
| 2023-09-30 | $536.00K | $1.53B | $-912.55M | $617.23M | $617.23M | (m) | 3 month · $10.94M | (m) | (m) |
| 2023-06-30 | $535.00K | $1.52B | $-934.46M | $581.68M | $581.68M | 3 month · $2.00K | 3 month · $10.10M | (m) | (m) |
| 2023-03-31 | $527.00K | $1.49B | $-879.87M | $607.41M | $607.41M | (m) | 3 month · $8.79M | (m) | (m) |
| 2022-12-31 | $521.00K | $1.45B | $-833.00M | $622.04M | $622.04M | (m) | 12 month · $31.32M | (m) | (m) |
| 2022-09-30 | $479.00K | $1.24B | $-839.35M | $404.65M | $404.65M | (m) | 3 month · $7.97M | (m) | (m) |
| 2022-06-30 | $468.00K | $1.20B | $-793.59M | $407.30M | $407.30M | (m) | 3 month · $8.26M | (m) | (m) |
| 2022-03-31 | $467.00K | $1.19B | $-752.34M | $438.89M | $438.89M | (m) | 3 month · $7.66M | (m) | (m) |
| 2021-12-31 | $466.00K | $1.18B | $-716.05M | $466.04M | $466.04M | (m) | 12 month · $24.66M | (m) | (m) |
| 2021-09-30 | $465.00K | $1.17B | $-682.88M | $490.47M | $490.47M | (m) | 3 month · $6.05M 9 month · $17.77M | (m) | (m) |
| 2021-06-30 | $449.00K | $1.08B | $-792.12M | $288.21M | $288.21M | 3 month · $5.00K | 3 month · $5.54M 6 month · $11.72M | (m) | (m) |
| 2021-03-31 | $442.00K | $1.05B | $-819.76M | $234.58M | $234.58M | (m) | 3 month · $6.18M | (m) | (m) |
| 2020-12-31 | $399.00K | $966.64M | $-783.03M | $184.01M | $184.01M | (m) | 12 month · $22.01M | (m) | (m) |
| 2020-09-30 | $399.00K | $961.43M | $-752.31M | $209.51M | $209.51M | (m) | 3 month · $5.58M 9 month · $16.81M | 3 month · $5.58M 9 month · $16.81M | (m) |
| 2020-06-30 | $399.00K | $955.78M | $-721.74M | $234.44M | $234.44M | (m) | 3 month · $5.69M 6 month · $11.22M | 3 month · $5.69M 6 month · $11.22M | (m) |
| 2020-03-31 | $399.00K | $950.09M | $-695.45M | $255.04M | $255.04M | (m) | 3 month · $5.54M | (m) | (m) |
| 2019-12-31 | $399.00K | $944.41M | $-671.88M | $272.92M | $272.92M | (m) | 12 month · $23.59M | (m) | (m) |
| 2019-09-30 | $399.00K | $939.11M | $-650.33M | $289.18M | $289.18M | (m) | 3 month · $5.82M 9 month · $18.30M | 3 month · $5.82M 9 month · $18.30M | (m) |
| 2019-06-30 | $399.00K | $933.29M | $-630.88M | $302.81M | $302.81M | (m) | 3 month · $6.28M 6 month · $12.48M | 3 month · $6.28M 6 month · $12.48M | (m) |
| 2019-03-31 | $399.00K | $926.80M | $-615.07M | $312.13M | $312.13M | (m) | 3 month · $6.21M | (m) | (m) |
| 2019-01-01 | (m) | (m) | $-594.21M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $399.00K | $920.59M | $-598.00M | $323.00M | $323.00M | (m) | 12 month · $26.06M | (m) | (m) |
| 2018-09-30 | $398.00K | $914.79M | $-575.53M | $339.65M | $339.65M | (m) | 3 month · $7.04M 9 month · $20.25M | (m) | (m) |
| 2018-06-30 | $398.00K | $906.58M | $-550.98M | $356.01M | $356.01M | (m) | 3 month · $6.31M 6 month · $13.21M | (m) | (m) |
| 2018-03-31 | $398.00K | $900.20M | $-491.09M | $409.50M | $409.50M | (m) | 3 month · $6.90M | (m) | (m) |
| 2017-12-31 | $385.00K | $849.15M | $-442.35M | $407.19M | $407.19M | 12 month · $4.90M | 12 month · $26.76M | (m) | (m) |
| 2017-09-30 | $384.00K | $840.46M | $-394.59M | $446.25M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $382.00K | $828.79M | $-342.20M | $486.98M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $380.00K | $820.37M | $-324.50M | $496.25M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $348.00K | $654.27M | $-289.21M | $365.40M | $365.40M | 12 month · $8.50M | 12 month · $24.93M | (m) | 12 month · $761.00K |
| 2016-09-30 | $344.00K | $641.06M | $-240.31M | $401.10M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $343.00K | $627.59M | $-197.07M | $430.87M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $343.00K | $622.06M | $-156.62M | $465.78M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $317.00K | $489.45M | $-129.10M | $360.67M | $360.67M | 12 month · $8.90M | 12 month · $10.41M | (m) | 12 month · $3.85M |
| 2015-09-30 | $315.00K | $482.58M | $-104.95M | $377.95M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $314.00K | $476.88M | $-81.97M | $395.22M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $275.00K | $340.84M | $-63.69M | $277.43M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $274.00K | $338.11M | $-48.49M | $289.89M | $289.89M | 12 month · $5.50M | 12 month · $5.60M | (m) | 12 month · $242.00K |
| 2014-09-30 | $274.00K | $336.67M | $-35.38M | $301.56M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $267.00K | $320.35M | $-22.20M | $298.42M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $219.00K | $216.28M | $-23.49M | $193.01M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $219.00K | $214.39M | $-41.34M | $173.27M | $173.27M | 12 month · $7.40M | 12 month · $3.13M | (m) | 12 month · $0.00 |
| 2013-09-30 | $177.00K | $128.89M | $-30.29M | $98.78M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $177.00K | $127.65M | $-20.60M | $107.23M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $177.00K | $126.91M | $-9.30M | $117.79M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $177.00K | $126.65M | $-345.00K | $126.48M | $126.48M | (m) | 12 month · $6.10M | (m) | 12 month · $0.00 |
| 2011-12-31 | (m) | (m) | (m) | (m) | $-6.44M | (m) | 12 month · $2.97M | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | $-30.00K | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |